Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- Keywords
- 1q21, chromosome aberrations, cytogenetic analysis, multiple myeloma, prognosis, treatment outcome,
- MeSH
- Chromosome Aberrations MeSH
- Humans MeSH
- Multiple Myeloma * diagnosis drug therapy etiology MeSH
- Prognosis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Multiple myeloma (MM) remains an incurable disease with a median overall survival of approximately 5 years. Gain or amplification of 1q21 (1q21+) occurs in around 40% of patients with MM and generally portends a poor prognosis. Patients with MM who harbor 1q21+ are at increased risk of drug resistance, disease progression, and death. New pharmacotherapies with novel modes of action are required to overcome the negative prognostic impact of 1q21+. Areas covered: This review discusses the detection, biology, prognosis, and therapeutic targeting of 1q21+ in newly diagnosed and relapsed MM. Patients with MM and 1q21+ tend to present with higher tumor burden, greater end-organ damage, and more co-occurring high-risk cytogenetic abnormalities than patients without 1q21+. The chromosomal rearrangements associated with 1q21+ result in dysregulation of genes involved in oncogenesis. Identification and characterization of the 1q21+ molecular targets are needed to inform on prognosis and treatment strategy. Clinical trial data are emerging that addition of isatuximab to combination therapies may improve outcomes in patients with 1q21+ MM. Expert opinion: In the next 5 years, the results of ongoing research and trials are likely to focus on the therapeutic impact and treatment decisions associated with 1q21+ in MM.
Department of Hematology University Hospital of Nantes Nantes France
Department of Medicine University of California San Francisco CA USA
Division of Hematology and Oncology University of Alabama at Birmingham Birmingham AL USA
Division of Hematology Department of Internal Medicine Mayo Clinic Rochester MN USA
Oncology Therapeutic Area Sanofi Research and Development Cambridge MA USA
Sanofi Research and Development Sanofi Vitry Sur Seine France
References provided by Crossref.org
